Amarantus BioScience Holdings (OTCPK:AMBS) - Stock Price, News & Analysis

AMBS Stock Overview

A biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. More details

AMBS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($63K)

Shares are highly illiquid

Amarantus BioScience Holdings, Inc. Competitors

Histogen

OTCPK:HSTO.Q

US$85.4k

Innovation Pharmaceuticals

OTCPK:IPIX

US$264.4k

Allena Pharmaceuticals

OTCPK:ALNA.Q

US$109.9k

Vaxxinity

OTCPK:VAXX

US$12.7k

Price History & Performance

Summary of all time highs, changes and price drops for Amarantus BioScience Holdings
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.04
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	-89.47%
33 Year Change	-98.80%
5 Year Change	-99.43%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	AMBS	US Biotechs	US Market
7D	0%	2.4%	0.5%
1Y	-89.5%	15.6%	30.7%

Return vs Industry: AMBS underperformed the US Biotechs industry which returned 18.8% over the past year.

Return vs Market: AMBS underperformed the US Market which returned 32.3% over the past year.

Price Volatility

Is AMBS's price volatile compared to industry and market?
AMBS volatility
AMBS Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: AMBS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AMBS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	n/a	Gerald Commissiong	www.amarantus.com

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson’s disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion.

Amarantus BioScience Holdings, Inc. Fundamentals Summary

How do Amarantus BioScience Holdings's earnings and revenue compare to its market cap?
AMBS fundamental statistics
Market cap	US$63.04k
Earnings (TTM)	-US$7.94m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is AMBS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AMBS income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$7.94m
Earnings	-US$7.94m

Last Reported Earnings

Jun 30, 2019

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did AMBS perform over the long term?

See historical performance and comparison